Read Gene

Read Gene Cash Flow per Share

The Operating Cash Flow per Share of Read Gene (RDG.WA) as of Oct 17, 2026 is -0.01 PLN. In the previous year, Operating Cash Flow per Share was 0.18 PLN — a change of -105.91% (lower).

Cash Flow per Share

-0.01PLN

YoY

-105.91%

Last updated:

Operating Cash Flow per Share of Read Gene is 2025 -0.01 PLN. Operating Cash Flow per Share of Read Gene was 2024 0.18 PLN. It decreases by -105.91% lower compared to the previous year.

The Read Gene Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-0.03 PLN
Jan 1, 2019
-0.27 PLN
Jan 1, 2020
0.12 PLN
Jan 1, 2021
9.01 PLN
Jan 1, 2022
29.24 PLN
Jan 1, 2023
-0.07 PLN
Jan 1, 2024
0.18 PLN
Jan 1, 2025
-0.01 PLN
The Read Gene Cash Flow per Share history
YEARCash Flow per ShareYoY
-0.01PLN-105.91%
0.18PLN-354.75%
-0.07PLN-100.24%
29.24PLN+224.65%
9.01PLN+7,166.03%
0.12PLN-146.70%
-0.27PLN+709.89%
-0.03PLN+13.62%
-0.03PLN-170.60%
0.04PLN-167.45%
-0.06PLN-68.82%
-0.19PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA is a biotechnology company based in Szczecin, Poland, operating within the Health Care sector. The company went public via an IPO on February 12, 2009, and is listed under the ticker RDG.WA with ISIN PLRADGN00014. Read Gene SA focuses on medical research and testing, particularly in the fields of chemoprevention, clinical trials, and genetic testing. Its services include specialized tests for breast cancer, colon cancer, and prostate cancer, alongside medical consultancy and DNA testing. The company also provides DNA-related supplements. It operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o., and its major shareholder is GEN-PAT-MED Sp. z o.o. The company's headquarters are located in Szczecin, within the West Pomeranian Voivodeship. Read Gene SA's activities are centered on developing technologies aimed at detecting, preventing, and treating malignant tumors. The company's website is https://read-gene.com/. No additional details regarding founding year, specific products, or financial figures are provided in the source material. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Operating Cash Flow per Share of Read Gene is -0.01 PLN in 2025.

Operating Cash Flow per Share of Read Gene changed from 0.18 PLN to -0.01 PLN, representing a -105.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Read Gene since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Read Gene

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Read Gene